Edition:
United States

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

3,635JPY
30 Sep 2016
Change (% chg)

¥-30 (-0.82%)
Prev Close
¥3,665
Open
¥3,640
Day's High
¥3,665
Day's Low
¥3,595
Volume
877,900
Avg. Vol
1,082,539
52-wk High
¥4,685
52-wk Low
¥3,110

Latest Key Developments (Source: Significant Developments)

Chugai Pharmaceutical to issue year-end dividend for FY 2014
Wednesday, 28 Jan 2015 02:30am EST 

Chugai Pharmaceutical Co Ltd:To issue a year-end dividend of 26 yen per share, for the FY ending Dec. 2014.Dividend issued to shareholders of record as of Dec. 31.Dividend payment date March 27.Says the dividend amount is above the latest forecast of 23 yen per share disclosed on Jan. 30, 2014.  Full Article

Chugai Pharmaceutical receives judgment of lawsuit
Thursday, 25 Dec 2014 01:00am EST 

Chugai Pharmaceutical Co Ltd:Received judgment of lawsuit from Tokyo District Court on Dec. 24.Filed a lawsuit against Iwaki Seiyaku Co.,Ltd, DKSH Japan K.K., POLA-Pharma and TAKATA SEIYAKU Co., Ltd. due to infringement of Chugai Pharmaceutical Co Ltd's patent of keratosis treatment agent (patent No. 3310301) of the four companies on Feb. 19, 2013.Judgment says provisional disposition instruction of import and sale injunction of the keratosis treatment agent for the four companies.  Full Article

Chiome Bioscience Inc announces joint research contract period extension with Chugai Pharmaceutical Co., Ltd.
Wednesday, 24 Dec 2014 01:00am EST 

Chiome Bioscience Inc:Announces joint research contract period extension to Dec. 31, 2015 with Chugai Pharmaceutical Co., Ltd.  Full Article

Chugai Pharmaceutical Co Ltd completes phase I results of Chugai’s Bispecific Antibody "ACE910" released at the American society of hematology meeting
Monday, 8 Dec 2014 10:00pm EST 

Chugai Pharmaceutical Co Ltd:Announces the phase I clinical data of anti-factor IXa x anti-factor X humanized bispecific antibody "ACE910," currently being developed for the indication of hemophilia A was presented at the 56th American Society of Hematology Annual Meeting on Dec. 8.Announces positive trial result on safety and efficacy of the ACE910.  Full Article

BRIEF-Chugai and Galderma announce global license agreement for Nemolizumab

* Chugai will continue to be responsible for product manufacturing and supply of Nemolizumab.